

BY E-MAIL

March 27, 2019

BSE Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023
E-mail : corp.relations@bseindia.com

Dear Sir,


Re: Declaration under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith disclosure for allotment to us of 16,75,095 equity shares of Rs. 10/- each of M/s. Krebs Biochemicals & Industries Limited in their Rights Equity Issue.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For and on behalf Ipca Laboratories Limited



Harish P. Kamath
Company Secretary



Encl: a/a

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.
E-mail : takeover@nse.co.in

Krebs Biochemicals and Industries Limited
Plot No 34, 8-2-577/B, Maas Heights,
3rd Floor, Road No 8,
Banjara Hills, Hyderabad 500034
E-mail : com_sec@krebbsbiochem.com

Ipca Laboratories Ltd.
www.ipca.com

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Krebs Biochemicals & Industries Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Ipca Laboratories Limited		
Whether the acquirer belongs to Promoter / Promoter Group	Yes. The acquirer is a promoter of TC.		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Ltd. (BSE); and The National Stock Exchange of India Ltd. (NSE)		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a. Shares carrying voting rights	41,00,100	29.83%	29.83%
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	41,00,100	29.83%	29.83%
Details of Acquisition			
a. Shares carrying voting rights acquired	16,75,095	10.07%	10.07%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+/-d)	16,75,095	10.07%	10.07%

WPU

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613
E: ipca@ipca.com | CIN: L24239MH1949PLC007837

After the acquisition, holding of			
a. Shares carrying voting rights	57,75,195	34.73%	34.73%
b. Shares encumbered with the acquirer	Nil	Nil	Nil
c. VRs otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e. Total (a+b+c+d)	57,75,195	34.73%	34.73%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter-se transfer etc.)	Allotted in Rights Issue		
Date of acquisition of shares / VR or date of receipt of intimation of allotment of shares, whichever applicable	26 th March, 2019 being intimation of allotment of shares in the rights issue.		
Equity share capital/total voting capital of the TC before the said acquisition (No. of equity shares)	1,37,44,286	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition (No. of equity shares)	1,66,30,586	100%	100%
Total diluted share/voting capital of the TC after the said acquisition/sale (No. of equity shares)	1,66,30,586	100%	100%

Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories Ltd.



Harish P. Kamath
Company Secretary

Place: Mumbai

Date: 27th March, 2019

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613
E: ipca@ipca.com | CIN: L24239MH1949PLC007837